Abstract
Peptide vaccines are in development as potential therapies for many major conditions, including chronic viral infections, allergies, cancer, Alzheimer’s disease, diabetes, hypertension, obesity, and rheumatoid arthritis. The therapeutic vaccines are known to induce neutralizing antibodies against self-molecules and have been clinically tested.
Active immunotherapy has been the most extensively studied approach in Aβ-targeted therapy. To improve the immunogenicity and reduce the adverse event, in the past decade progress of active immunotherapy has been made both in the selection of B cell epitope and the carrier protein. Progress made in peptide-based vaccinations to induce antibody has invigorated the search for vaccine modalities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cease KB et al (1987) Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A 84:4249–4253
Davtyan H et al (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci 33:4923–4934
Gilman S et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562
Hernandez I et al (2018) Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care 24:109–112
Nakagami H, Morishita R (2018) Recent advances in therapeutic vaccines to treat hypertension. Hypertension 72:1031–1036
Nandy A, Basak SC (2016) A brief review of computer-assisted approaches to rational design of peptide vaccines. Int J Mol Sci 17
Wang CY, Walfield AM (2005) Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 23:2049–2056
Wiessner C et al (2011) The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31:9323–9331
Winblad B et al (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597–604
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Tomioka, H., Tenma, A., Sakaguchi, M. (2019). Translational Research of Novel Peptide Vaccine. In: Nakagami, H. (eds) Therapeutic Vaccines as Novel Immunotherapy. Springer, Singapore. https://doi.org/10.1007/978-981-32-9628-2_7
Download citation
DOI: https://doi.org/10.1007/978-981-32-9628-2_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9627-5
Online ISBN: 978-981-32-9628-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)